Brexpiprazole (Rexulti) was recently approved by the FDA for treatment of agitation in Alzheimer Dementia based on the now published phase 3 study found in JAMA Neurology, November 6, 2023. In this 12-week study of the efficacy of this medication at the 2 and 3 mg daily dose compared to placebo, a statistically significant improvement in agitation was noted vs placebo. This medication was generally well tolerated without significant safety adverse events. Agitation was defined as 1. excessive motor activity, 2. verbal aggression, or 3. physical aggression which caused excess distress or disability and could not be safely attributed to a suboptimal care environment or another disorder. This is a small short-term study across multiple sites and countries. This medication should be used for this indication with great caution until further studies confirm these results and better define those who might benefit, the degree of the benefit, and if significant long term adverse events occur with more prolonged use. This medicine has common drug interactions that warrant dose adjustment in many circumstances. This link has the details.